Gelesis Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 56

Employees

  • Latest Deal Type
  • M&A

Gelesis General Information

Description

Gelesis Holdings Inc is a commercial-stage biotherapeutics company built for consumer engagement. The company is focused on advancing its superabsorbent hydrogel therapeutics for chronic gastrointestinal diseases, including excess weight, type 2 diabetes, non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH), functional constipation (FC), and inflammatory bowel disease. It manufactures and markets Plenity, which is based on a proprietary hydrogel technology, to aid in weight management when used in conjunction with diet and exercise. Geographically, the company operates out of the U.S. and Italy.

Contact Information

Website
www.gelesis.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Via Europa, SP26, 187
  • Suite 6102
  • 73021 Calimera(Leece)
  • Italy
+39 0832
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Theras Group
Vertical(s)
Corporate Office
  • Via Europa, SP26, 187
  • Suite 6102
  • 73021 Calimera(Leece)
  • Italy
+39 0832

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gelesis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
24. Merger/Acquisition 08-Jul-2024 Completed Generating Revenue
23. Bankruptcy: Admin/Reorg 30-Oct-2023 Completed Bankruptcy: Admin/Reorg
22. PIPE 11-Aug-2022 Completed Generating Revenue
21. PIPE 14-Jan-2022 Completed Generating Revenue
20. Reverse Merger 13-Jan-2022 Completed Generating Revenue
19. Debt - General 01-Mar-2021 Completed Generating Revenue
18. Secondary Transaction - Private 18-Jan-2021 Completed Generating Revenue
17. Debt - General 31-Dec-2020 Completed Generating Revenue
16. Later Stage VC 29-Jul-2020 $84.6M $305M Completed Generating Revenue
15. Debt - PPP 15-Apr-2020 $297K $220M Completed Generating Revenue
To view Gelesis’s complete valuation and funding history, request access »

Gelesis Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series 4 Growth
Series 3 Growth
Series 2 Growth
Growth Pref
Series A5
Series A4
Series A3
Series A2 1,161,254 $0.000100 8% $2.61 $2.61 1x $2.61 3.51%
Series A1 1,711,755 $0.000100 8% $4.44 $4.44 1x $4.44 5.18%
To view Gelesis’s complete cap table history, request access »

Gelesis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Gelesis Holdings Inc is a commercial-stage biotherapeutics company built for consumer engagement. The company is focused
Drug Discovery
Calimera, Italy
56 As of 2026

Campbell, CA
 

Yardley, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Gelesis Competitors (28)

One of Gelesis’s 28 competitors is Vivus, a Corporate Backed or Acquired company based in Campbell, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vivus Corporate Backed or Acquired Campbell, CA
Savara Formerly VC-backed Yardley, PA
Sharp Therapeutics (Biotechnology) Formerly VC-backed Pittsburgh, PA
uniQure Formerly VC-backed Amsterdam, Netherlands
Immunocore Holdings Formerly VC-backed Abingdon, United Kingdom
You’re viewing 5 of 28 competitors. Get the full list »

Gelesis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Gelesis Former Investors (28)

Investor Name Investor Type Holding Investor Since Participating Rounds
Andera Partners PE/Buyout Minority
BIRD Foundation Limited Partner
BRC Group Holdings Holding Company Minority
Cape Family Fund Venture Capital Minority
Capstar Special Purpose Acquisition Special Purpose Acquisition Company (SPAC) Minority
You’re viewing 5 of 28 investors. Get the full list »

Gelesis Acquisitions (2)

Gelesis’s most recent deal was a Merger/Acquisition with Capstar Special Purpose Acquisition. The deal was made on 13-Jan-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Capstar Special Purpose Acquisition 13-Jan-2022 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
Academica Life Science 01-Feb-2015 Merger/Acquisition Industrial Chemicals
To view Gelesis’s complete acquisitions history, request access »

Gelesis ESG

Risk Overview

Risk Rating

Updated April, 30, 2023

29.2 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,942

Rank

Percentile

Pharmaceuticals

Industry

of 914

Rank

Percentile

Biotechnology

Subindustry

of 412

Rank

Percentile

To view Gelesis’s complete esg history, request access »

Gelesis FAQs

  • When was Gelesis founded?

    Gelesis was founded in 2006.

  • Where is Gelesis headquartered?

    Gelesis is headquartered in Calimera, Italy.

  • What is the size of Gelesis?

    Gelesis has 56 total employees.

  • What industry is Gelesis in?

    Gelesis’s primary industry is Drug Discovery.

  • Is Gelesis a private or public company?

    Gelesis is a Private company.

  • What is Gelesis’s current revenue?

    The current revenue for Gelesis is .

  • How much funding has Gelesis raised over time?

    Gelesis has raised $422M.

  • Who are Gelesis’s investors?

    Andera Partners, BIRD Foundation, BRC Group Holdings, Cape Family Fund, and Capstar Special Purpose Acquisition are 5 of 28 investors who have invested in Gelesis.

  • Who are Gelesis’s competitors?

    Vivus, Savara, Sharp Therapeutics (Biotechnology), uniQure, and Immunocore Holdings are some of the 28 competitors of Gelesis.

  • When was Gelesis acquired?

    Gelesis was acquired on 08-Jul-2024.

  • Who acquired Gelesis?

    Gelesis was acquired by Theras Group.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process